PXDN and prostate adenocarcinoma: As shown by Figure 11A, the expression of PXDN was negatively correlated with TMB in LIHC, Head and Neck squamous cell carcinoma (HNSC), Prostate adenocarcinoma (PRAD), and STAD, and the p-values were statistically significant.